Literature DB >> 2112162

Adverse dermatologic reactions to transdermal drug delivery systems.

D J Hogan1, H I Maibach.   

Abstract

Transdermal drug delivery systems are marketed in the United States for four different drugs, and others are in various stages of development. Cutaneous side effects occur frequently with these systems and sometimes necessitate discontinuation of therapy. This article will review these adverse reactions.

Mesh：

Substances：

Year:  1990        PMID： 2112162     DOI： 10.1016/0190-9622(90)70113-v

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN： 0190-9622            Impact factor:   11.527


  8 in total

1.  Percutaneous absorption enhancement of leuprolide.

Authors:  M Y Lu; D Lee; G S Rao
Journal:  Pharm Res       Date:  1992-12       Impact factor: 4.200

Review 2.  Transdermal patches: history, development and pharmacology.

Authors:  Michael N Pastore; Yogeshvar N Kalia; Michael Horstmann; Michael S Roberts
Journal:  Br J Pharmacol       Date:  2015-03-18       Impact factor: 8.739

3.  Chemical Leukoderma Associated with Methylphenidate Transdermal System: Data From the US Food and Drug Administration Adverse Event Reporting System.

Authors:  Carmen Cheng; Lois La Grenade; Ida-Lina Diak; Allen Brinker; Robert L Levin
Journal:  J Pediatr       Date:  2016-10-10       Impact factor: 4.406

4.  Predictors and timing of adverse experiences during trandsdermal nicotine therapy.

Authors:  S G Gourlay; A Forbes; T Marriner; J J McNeil
Journal:  Drug Saf       Date:  1999-06       Impact factor: 5.606

Review 5.  A risk-benefit appraisal of transdermal estradiol therapy.

Authors:  A Cheang; R Sitruk-Ware; W H Utian
Journal:  Drug Saf       Date:  1993-11       Impact factor: 5.606

6.  Efficacy and safety of two different galenic formulations of a transdermal clonidine system in the treatment of hypertension.

Authors:  R E Kolloch; L Mehlburger; H Schumacher; B O Göbel
Journal:  Clin Auton Res       Date:  1993-12       Impact factor: 4.435

7.  Long-term (5 year) experience with transdermal clonidine in the treatment of mild to moderate hypertension.

Authors:  J Breidthardt; H Schumacher; L Mehlburger
Journal:  Clin Auton Res       Date:  1993-12       Impact factor: 4.435

Review 8.  Skin sensitivity and transdermal drug delivery. A review of the problem.

Authors:  A J Carmichael
Journal:  Drug Saf       Date:  1994-02       Impact factor: 5.606
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.